Plain-English translation of NCT04853251 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a tiny surgical implant called the Port Delivery System (PDS) filled with ranibizumab, a medication that fights the abnormal blood vessel growth seen in wet age-related macular degeneration. Instead of getting frequent eye injections, participants would have this implant surgically placed in the eye, and it would be refilled with the medication every 6 months. The study will monitor how the implant affects the cornea (the clear front part of the eye) over time.
Wet age-related macular degeneration requires frequent eye injections to slow vision loss, which can be burdensome for patients. This trial is testing whether a surgically implanted device that slowly releases the medication could be a more convenient long-term option while keeping the eye healthy.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will have surgery to place the small implant in your study eye on the first day. After that, you will return for refill-exchange procedures every 24 weeks (about every 6 months), where the implant is refilled with fresh medication. Throughout the study, you will have regular eye exams, vision tests, and specialized imaging scans (including photos and tests to check how the implant is affecting your cornea). The study involves 188 participants and is still recruiting patients.
AI-generated summary from trial data · Oct 5, 2026 · Not medical advice
United States